USPTO Examiner HUTSON RICHARD G - Art Unit 1652

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18998009METHODS OF USING SYNTROPHUS ACIDITROPHICUS TO PRODUCE CYCLOHEXANE-1-CARBOXYLATE (CHC)January 2025March 2026Allow1401YesNo
19014260PFU DNA POLYMERASE MUTANTS WITH REVERSE TRANSCRIPTASE ACTIVITY AND THEIR APPLICATIONSJanuary 2025October 2025Allow911YesNo
18742500High Throughput Reaction AssemblyJune 2024January 2026Allow1910NoNo
18660667DNA POLYMERASE MUTANT SUITED TO NUCLEIC ACID AMPLIFICATION FROM RNAMay 2024April 2025Allow1110YesNo
18628140ENGINEERED GLUCOSYLTRANSFERASESApril 2024April 2025Allow1211YesNo
18597204RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAMEMarch 2024March 2026Allow2411YesNo
18435579NOVEL CRISPR-ASSOCIATED (CAS) PROTEINFebruary 2024August 2025Abandon1801NoNo
18393303CASZ COMPOSITIONS AND METHODS OF USEDecember 2023December 2024Abandon1211NoNo
18393318CASZ COMPOSITIONS AND METHODS OF USEDecember 2023December 2025Abandon2421NoNo
18544190RECOMBINANT POLYMERASES FOR INCORPORATION OF PROTEIN SHIELD NUCLEOTIDE ANALOGSDecember 2023January 2026Abandon2521NoNo
18569989ENZYMATIC METHOD FOR THE PRODUCTION OF L-GLUFOSINATE P-ALKYL ESTERSDecember 2023June 2025Allow1831YesNo
18521466POLYMERASE COMPOSITIONS AND KITS, AND METHODS OF USING AND MAKING THE SAMENovember 2023April 2025Allow1711YesNo
18510933ENZYME-PORE CONSTRUCTSNovember 2023October 2025Abandon2311NoNo
18481401MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTIONOctober 2023November 2025Allow2521YesNo
18478512TELA VARIANTS, COMPOSITIONS, AND METHODSSeptember 2023April 2024Allow621YesNo
18476104MUTANT POLYMERASES AND USES THEREOFSeptember 2023January 2025Allow1611YesNo
18472046Compositions and Methods Related to Nucleic Acid SynthesisSeptember 2023April 2025Abandon1920NoNo
18464955POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORSSeptember 2023February 2024Allow510NoNo
18462868Vaccinia Capping Enzyme Compositions and MethodsSeptember 2023January 2025Allow1711YesNo
18458762METHODS FOR PRODUCTION OF NOVEL DITERPENE SCAFFOLDSAugust 2023September 2025Allow2511YesNo
18365105EVOLUTION OF PROTEASESAugust 2023May 2025Abandon2121NoNo
18223387RECOMBINANT POLYMERASES FOR IMPROVED SINGLE MOLECULE SEQUENCINGJuly 2023September 2025Abandon2621NoNo
18219045MUTANT DNA POLYMERASE(S) WITH IMPROVED STRAND DISPLACEMENT ABILITYJuly 2023December 2024Allow1711YesNo
18343727PROCESSES FOR PRODUCING REDUCED COENZYME Q10June 2023November 2024Allow1731YesNo
18343131DNase VariantsJune 2023May 2024Allow1011YesNo
18259225Modified DNA PolymeraseJune 2023March 2026Abandon3310NoNo
18323660Taq DNA Polymerase Variants with Increased Reverse Transcriptase ActivityMay 2023August 2025Allow2710YesNo
18195702T4 DNA Ligase Variants with Increased Resistance to SaltMay 2023May 2025Allow2411YesNo
18298291Compositions and Analysis of Dephosphorylated OligoribonucleotidesApril 2023October 2024Allow1941YesNo
18130012Process of Probe qPCR Using Taq DNA Polymerase MutantsApril 2023June 2024Allow1440YesNo
18129292Protein Enriched Microvesicles and Methods of Making and Using the SameMarch 2023February 2025Allow2311YesNo
18029787VACUUM DRYING METHOD FOR BOTULINUM TOXINMarch 2023January 2026Allow3310NoNo
18191774ALDEHYDE DEHYDROGENASE VARIANTS AND METHODS OF USING SAMEMarch 2023March 2025Allow2421YesNo
18125661NOVEL REVERSE TRANSCRIPTASES AND USES THEREOFMarch 2023April 2024Allow1301YesNo
18176502COMPOSITIONS AND METHODS FOR ENHANCING REVERSE TRANSCRIPTASE ACTIVITY AND/OR REDUCING THE INHIBITION OF REVERSE TRANSCRIPTASEMarch 2023February 2025Allow2311NoNo
18023229ENZYMATIC DEGRADATION OF CELLULOSIC SUBSTRATES IN THE PRESENCE OF LIGNOCELLULOSE MILLING PARTICLESFebruary 2023January 2026Abandon3401NoNo
18022898OLEAGINOUS YEAST STRAIN AND USE THEREOF FOR THE PRODUCTION OF LIPIDSFebruary 2023November 2025Allow3310YesNo
18042244Botulinum Neurotoxin Proteins and Methods to Engineer and Generate SameFebruary 2023January 2026Abandon3401NoNo
18160952ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORSJanuary 2023August 2024Allow1821YesNo
18160951ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORSJanuary 2023January 2024Allow1211YesNo
18154437METHOD FOR ADDING CAP STRUCTURES TO RNA USING IMMOBILIZED ENZYMESJanuary 2023March 2025Abandon2601NoNo
18069898CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINSDecember 2022April 2025Allow2821YesNo
18080926MODIFIED ß-GALACTOSIDASEDecember 2022October 2024Abandon2211NoNo
18055966DP04 POLYMERASE VARIANTS WITH IMPROVED ACCURACYNovember 2022April 2025Abandon2921NoNo
17924637MUTANT POLYMERASES AND METHODS OF USING THE SAMENovember 2022August 2025Allow3311YesNo
18048388MODIFIED THERMOCOCCUS POLYMERASESOctober 2022July 2024Allow2111YesNo
18046451ENGINEERED TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTSOctober 2022October 2025Allow3641YesNo
17936144High Throughput Reaction AssemblySeptember 2022May 2024Allow2010YesNo
17935406POLYMERASE COMPOSITIONS & METHODSSeptember 2022July 2024Allow2211YesNo
17935521CASZ COMPOSITIONS AND METHODS OF USESeptember 2022October 2024Abandon2511NoNo
17910349ENZYMES WITH IMPROVED THERMOSTABILITY FOR THE DEGRADATION OF PLASTIC PRODUCTSSeptember 2022June 2025Abandon3311NoNo
17896147ALPHA-AMYLASE VARIANTSAugust 2022May 2024Allow2011NoNo
17894854POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORSAugust 2022July 2023Allow1111YesNo
17892224COMPOSITIONS AND METHODS FOR TREATING DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIAAugust 2022July 2025Abandon3501NoNo
17796518MANNANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEJuly 2022July 2025Allow3611YesNo
17812156HUMAN GUT MICROBIOME-DERIVED BIOSYNTHETIC ENZYMES FOR PRODUCTION OF FATTY ACID AMIDESJuly 2022July 2025Abandon3601NoNo
17857480RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEXJuly 2022September 2025Allow3911YesNo
17808128ENGINEERED DEAMINASESJune 2022July 2024Allow2511NoNo
17841429METHODS FOR GENOMIC INTEGRATION IN PICHIA AND OTHER HOST CELLSJune 2022August 2024Allow2620YesNo
17838852IMMOBILIZED POLY(N)POLYMERASEJune 2022April 2024Abandon2201NoNo
17743859COMPOSITIONS AND METHODS FOR IDENTIFYING RNA BINDING POLYPEPTIDE TARGETSMay 2022November 2023Allow1811YesNo
17742033Thermostable Variants of T7 RNA PolymeraseMay 2022May 2024Allow2421YesNo
17735129ASPERGILLUS ORYZAE AND ITS APPLICATIONMay 2022June 2024Allow2510YesNo
17728573GLYCOSYLATED LYSOSOMAL PROTEINS, METHOD OF PRODUCTION AND USESApril 2022November 2024Allow3121YesYes
17725369POLYMERASE COMPOSITIONS AND METHODS OF MAKING AND USING SAMEApril 2022September 2024Allow2931YesNo
17724342GRIFFITHSIN MUTANTSApril 2022April 2025Allow3630YesNo
17705020ENGINEERED POLYMERASESMarch 2022November 2024Allow3241YesNo
17705043ENGINEERED POLYMERASESMarch 2022July 2024Allow2740YesNo
17653913RECOMBINANT MICROORGANISMS AND USES THEREFORMarch 2022July 2025Abandon4031NoNo
17678369NOVEL CRISPR-ASSOCIATED (CAS) PROTEINFebruary 2022November 2023Allow2101YesNo
17677655T4 DNA Ligase Variants with Increased ThermostabilityFebruary 2022August 2023Allow1820YesNo
17676546TYPE II CRISPR/CAS9 GENOME EDITING SYSTEM AND THE APPLICATION THEREOFFebruary 2022September 2024Allow3121YesNo
17675278T4 DNA Ligase Variants with Increased Resistance to SaltFebruary 2022May 2023Allow1511YesNo
17673279PROGRAMMABLE DNA-GUIDED ARTIFICIAL RESTRICTION ENZYMESFebruary 2022April 2024Abandon2611YesNo
17586234METHOD FOR ENHANCING PRODUCTION OF HOMEOPROTEIN USING INHIBITOR OF LYSOSOMAL FUNCTIONJanuary 2022July 2024Allow2921YesNo
17629316Template-Free Enzymatic Synthesis of Polynucleotides Using Poly(A) and Poly(U) PolymerasesJanuary 2022December 2025Allow4611YesNo
17628581DISHWASHING AGENT WITH BLEACHING CATALYST AND BACILLUS GIBSONII PROTEASEJanuary 2022December 2025Allow4730NoNo
17625395BIOTECHNOLOGICAL PRODUCTION OF DIOLSJanuary 2022February 2025Allow3720YesNo
17564500ENGINEERED POLYMERASES FOR IMPROVED SEQUENCINGDecember 2021October 2023Allow2210NoNo
17563794PREPARATION METHOD OF HIGH-STABILITY SUPEROXIDE DISMUTASE WITH TRANSMEMBRANE CAPABILITYDecember 2021December 2023Allow2311YesNo
17623542GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING DIAMINE COMPOUNDDecember 2021May 2025Abandon4111NoNo
17645146POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAMEDecember 2021February 2025Allow3851YesNo
17554012Compositions and Methods Related to Nucleic Acid SynthesisDecember 2021June 2023Allow1801YesNo
17553455KETOREDUCTASE POLYPEPTIDES FOR THE SYNTHESIS OF CHIRAL COMPOUNDSDecember 2021May 2025Allow4141YesNo
17544668GLUCOAMYLASES AND METHODS OF USE, THEREOFDecember 2021January 2024Abandon2620NoNo
17531220DNase VariantsNovember 2021April 2023Allow1711YesNo
17595643LINALOOL SYNTHASESNovember 2021February 2025Allow3911YesNo
17612799STRAIN OF MICROORGANISMS AND PROCESS FOR THE FERMENTATIVE PRODUCTION OF GAMMA-GLUTAMYLTYROSINE AND GAMMA-GLUTAMYLPHENYLALANINENovember 2021January 2026Abandon5010NoNo
17523670RECOMBINANT POLYMERASES FOR INCORPORATION OF PROTEIN SHIELD NUCLEOTIDE ANALOGSNovember 2021September 2023Allow2211YesNo
17514043BIOSYNTHESIS OF VANILLIN FROM ISOEUGENOLOctober 2021January 2025Abandon3910NoNo
17500831MODIFIED ENZYMESOctober 2021December 2023Allow2611YesNo
17603359METHOD OF PURIFYING BOTULINUM TOXINOctober 2021February 2026Allow5241YesNo
17603326METHOD OF PURIFYING BOTULINUM TOXINOctober 2021March 2026Allow5341YesNo
17485606METHOD OF SCREENING INHIBITOR OF CASPASE ACTIVITY BY LIPOPOLYSACCHARIDESeptember 2021January 2024Allow2730YesNo
17485004MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUESSeptember 2021August 2024Allow3531YesYes
17470557Taq DNA Polymerase Mutants for Probe qPCRSeptember 2021March 2023Allow1821YesNo
17437566PROCESS FOR PRODUCING A FERMENTATION BROTHSeptember 2021July 2024Allow3521YesNo
17410647MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUESAugust 2021June 2022Allow1021YesNo
17373314METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDSJuly 2021December 2024Abandon4132NoNo
17421967RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOFJuly 2021March 2025Allow4411YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUTSON, RICHARD G.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
27
Examiner Affirmed
15
(55.6%)
Examiner Reversed
12
(44.4%)
Reversal Percentile
66.9%
Higher than average

What This Means

With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
182
Allowed After Appeal Filing
46
(25.3%)
Not Allowed After Appeal Filing
136
(74.7%)
Filing Benefit Percentile
36.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HUTSON, RICHARD G - Prosecution Strategy Guide

Executive Summary

Examiner HUTSON, RICHARD G works in Art Unit 1652 and has examined 1,119 patent applications in our dataset. With an allowance rate of 56.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner HUTSON, RICHARD G's allowance rate of 56.6% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HUTSON, RICHARD G receive 2.49 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HUTSON, RICHARD G is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +50.4% benefit to allowance rate for applications examined by HUTSON, RICHARD G. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.1% of cases where such amendments are filed. This entry rate is in the 48% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 92.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.5% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 62.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.4% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.5% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.4% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.